<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02692248</url>
  </required_header>
  <id_info>
    <org_study_id>IBDCL-GELTAMO-2015</org_study_id>
    <nct_id>NCT02692248</nct_id>
  </id_info>
  <brief_title>Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation</brief_title>
  <official_title>Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to ASCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric phase II trial to evaluate efficacy and safety of ibrutinib in combination with
      rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maitenance in
      patients with refractory/relapsed non-GCB DLBCL non candidates to autologous stem-cell
      transplantation (ASCT) An extensive biological study will be conducted in order to further
      characterize this population of DLBCL patients and correlate the response obtained with the
      biological profile of the tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of highly effective rituximab-containing therapy for treating diffuse large B-cell
      lymphoma (DLBCL) makes it more difficult to salvage relapsed or refractory patients. In
      addition, patients with advanced age or significant comorbidities, who are consequently not
      candidates for high-dose consolidative therapy, have a very poor prognosis. Prospective
      studies investigating new salvage regimens are essential.

      The combination of rituximab, gemcitabine and oxaliplatin (R-GEMOX) is an effective salvage
      regimen for patients with relapsing or refractory DLBCL, with a favourable toxicity profile
      for unfit and/or elderly patients. Ibrutinib, an oral Bruton's tyrosine kinase inhibitor, is
      a potent killer of ABC DLBCL cell lines in vitro and in xenografts.

      It is expected that the combination of ibrutinib with R-GEMOX-Dexa could be effective and
      well tolerated. Thus, it is proposed an open-label, non-randomized, multicentre, phase II
      trial, to investigate the safety and efficacy of the combination of ibrutinib with rituximab,
      gemcitabine, oxaliplatine and dexamethasone followed by ibrutinib maintenance as salvage
      therapy for patients with relapsed or refractory non-GCB DLBCL non-candidates to stem cell
      transplant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response (OR) rate (complete remission + partial response) measured by PET(Positron Emission Tomography)/CT imagen scan</measure>
    <time_frame>Treatment responses will be evaluated 30 days after end of study treatment wich can be ocurred after 2 years and 4 months</time_frame>
    <description>OR will be assessed by Lugano Classification: Revised Criteria for Response Assessment (Cheson et al. 2014)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR rate during induction and maintenance phases.</measure>
    <time_frame>2 years</time_frame>
    <description>Complete treatment responses evaluation during 21-35 days after initiation of 6 or 8 cycle of study treatment (depend of treatment responses obtained from cycle 4) and 30 days after end of study treatment which can be occurred after 2 years and 4 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion rate from SD (Stable Disease) or PR to PR or CR by PET/CT imagen scan</measure>
    <time_frame>2 years</time_frame>
    <description>Responses conversion rate evaluation after 30 days of the end of the maintenance treatment which can be occurred after 2 years of maintenance study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>Response duration will be evaluated at any time during the study when tumor response is documented or after end of study treatment which can be occurred after 2 years and 4 months.</time_frame>
    <description>Response duration defined as the time from the documentation of tumor response to disease progression or death, in the event of no documented recurrence, or start of a new anti - lymphoma treatment because of refractory or persistent disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Progression free survival will be evaluated at any time during the study when first documentation of recurrence, progression, or death or after end of study treatment which can be occurred after 2 years and 4 months</time_frame>
    <description>Progression free survival defined as the time between start of treatment and the first documentation of recurrence, progression, or death in the event of no documented recurrence, or start of a new anti - lymphoma treatment, due a refractory or persistent disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Event-free survival defined as the time between start of treatment and the first documentation of adverse events and serious adverse events graded according to NCI CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival is defined as the time between the start of treatment and death from any cause. Patients that are withdrawn from the trial or lost of follow-up, will be censored with the date of last contact. Patients who are still alive at the end of the study will be censored at that time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of ibrutinib in combination rituximab, gemcitabine, oxaliplatin and dexamethasone</measure>
    <time_frame>2 years</time_frame>
    <description>Safety and tolerability will be assessed during any phase of study treatment and 30 days after end of study treatment which can be occurred after 2 years and 4 months and will be classified according to the Common Toxicity CNC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Ibrutinib -R-GEMOX-Dexa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Ibrutinib with R-GEMOX-Dexa followed by Ibrutinib maintenance according to:
Induction phase:
Rituximab 375 mg/m2 IV day 1
Gemcitabine 1000 mg/msq IV on day 1 or 2 (at investigator discretion).
Oxaliplatine 100 mg/msq on day 1 or 2 (after Gemcitabine administration);
Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3.
Ibrutinib 560 mg daily for 14 days.
Responding patients will receive 2 (if CR) or 4 (if PR) additional cycles every 14 days.Patients with SD and ABC profile will receive 4 additional cycles.
Maintenance phase: Responding patients will receive Ibrutinib 560 mg daily - Continuous cycles until a maximum of 2 years, disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).</description>
    <arm_group_label>Ibrutinib -R-GEMOX-Dexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m2 IV day 1 during 4 cycles.</description>
    <arm_group_label>Ibrutinib -R-GEMOX-Dexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000 mg/msq IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.</description>
    <arm_group_label>Ibrutinib -R-GEMOX-Dexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 100 mg/msq (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.</description>
    <arm_group_label>Ibrutinib -R-GEMOX-Dexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.</description>
    <arm_group_label>Ibrutinib -R-GEMOX-Dexa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with confirmed histologically diagnosis of diffuse large B-cell lymphoma.

          2. Subjects must be 18 years of age or older.

          3. Non-germinal center B-cell-like (GCB) subtype according to Hans algorithm (local
             laboratories).

          4. Relapsed or refractory disease after:

               -  at least 1 prior line of therapy that includes rituximab in combination with
                  chemotherapy, or,

               -  after previous ASCT, or,

               -  after reduced intensity conditioning allogeneic transplant, unless patient is
                  receiving immunosuppressive drugs or active graft versus host disease is present
                  at study entry.

          5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

          6. Baseline FDG-PET scan demonstrating positive lesions (Deauville 4 or 5) compatible
             with CT defined anatomical tumor sites.

          7. Hematology values must be within the following limits:

               1. absolute neutrophil count (ANC) ≥1000/μL independent of growth factor support.

               2. platelets ≥100000/μL or ≥50000/μL if bone marrow involvement independent of
                  transfusion support in either situation.

          8. Biochemical values within the following limits:

               1. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x upper
                  limit of normal (ULN).

               2. total bilirubin ≤1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or
                  of non-hepatic origin.

               3. serum creatinine ≤2 x ULN or estimated creatinine clearance (CCr) ≥30 mL/min.

          9. Women of childbearing potential and men who are sexually active must be practicing a
             highly effective method of birth control during and after the study consistent with
             local regulations regarding the use of birth control methods for subjects
             participating in clinical trials. Men must agree to not donate sperm during and after
             the study. For females, these restrictions apply for 1 month after the last dose of
             study drug. For males, these restrictions apply for 3 months after the last dose of
             study drug.

         10. Women of childbearing potential must have a negative serum (beta-human chorionic
             gonadotropin) or urine pregnancy test at Screening. Women who are pregnant or
             breastfeeding are ineligible for this study.

         11. Sign (or their legally-acceptable representatives must sign) an informed consent
             document indicating that they understand the purpose of and procedures required for
             the study and are willing and able to participate in the study.

        Exclusion Criteria:

          1. Prior malignancy other than DLBCL, with the exception of adequately treated basal cell
             or squamous cell skin tumor, in situ cervical cancer, or other tumor from which the
             patient has been disease free for at least 2 years or which will not limit survival to
             &lt; 2 years (Note: these cases must be discussed with the Principal Investigator).

          2. Candidates to autologous stem cell transplant.

          3. Any life-threatening illness, medical condition or organ system dysfunction which, in
             the investigator's opinion, could compromise the patient's safety,interfere with the
             absorption or metabolism of ibrutinib, or put the study outcomes at undue risk.

          4. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
             congestive heart failure, or myocardial infarction within 6 months of screening, or
             any Class 3 or 4 cardiac disease as defined by the New York Heart Association
             Functional Classification.

          5. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel or ulcerative colitis,symptomatic inflammatory
             bowel disease, or partial or complete bowel obstruction.

          6. Treatment with any immunotherapy, chemotherapy, radiotherapy, or experimental therapy
             within 3 weeks before first dose of study drug.

          7. Prior treatment with ibrutinib or other BTK inhibitors.

          8. Central nervous system (CNS) involvement by lymphoma.

          9. History of stroke or intracranial hemorrhage within 6 months prior to randomization.

         10. Requires anticoagulation with warfarin or equivalent Vitamin K antagonists.

         11. Requires treatment with strong CYP3A inhibitors.

         12. Grade ≥2 toxicity (other than alopecia) related to prior anticancer therapy including
             radiation.

         13. Known history of human immunodeficiency virus (HIV), active hepatitis C virus (HCV)
             (HCV; RNA polymerase chain reaction [PCR]-positive) or active Hepatitis B virus (HBV;
             DNA PCR-positive) infection or any uncontrolled active systemic infection requiring IV
             antibiotics. Subjects with PCR-negative HBV are permitted in the study.

         14. Major surgery within 4 weeks before first dose of study drug.

         15. Vaccinated with live, attenuated vaccines within 4 weeks of randomization.

         16. Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dolores Caballero, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario de Salamanca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dolores Caballero, MD</last_name>
    <email>cabarri@usal.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alejandro Martín García-Sancho, MD</last_name>
    <email>amartingar@usal.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Ramírez Páyer, MD</last_name>
      <email>apayer.angel@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ángel Ramírez Páyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Especialidades</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª José Ramírez, MD</last_name>
      <email>mariajoserasa@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Mª José Ramírez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>Donostia San Sebastian</city>
        <state>Guipúzcoa</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izaskun Ceberio, MD</last_name>
      <email>IZASKUN.CEBERIOECHECHIPIA@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Izaskun Ceberio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Gutiérrez, MD</last_name>
      <email>antoniom.gutierrez@ssib.es</email>
    </contact>
    <investigator>
      <last_name>Antonio Gutiérrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Cruz Viguria, MD</last_name>
      <email>mc.viguria.alegria@cfnavarra.es</email>
    </contact>
    <investigator>
      <last_name>Mª Cruz Viguria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Margarita Martínez Castro, MD</last_name>
      <email>ana.margarita.martinez.castro@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Ana Margarita Martínez Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pau Abrisqueta, MD</last_name>
      <email>pabrisqueta@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Pau Abrisqueta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Giné, MD</last_name>
      <email>EGINE@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Eva Giné, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soledad Duran Nieto, MD</last_name>
      <email>soledaduran@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Soledad Durán Nieto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Antonio Hernández Rivas, MD</last_name>
      <email>jahr_jahr2006@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Jose Antonio Hernández Rivas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo de la Fuente, MD</last_name>
      <email>afuente@mdanderson.es</email>
    </contact>
    <investigator>
      <last_name>Adolfo de la Fuente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Grande, MD</last_name>
      <email>cgrandegar@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Carlos Grande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Javier Sánchez Blanco, MD</last_name>
      <email>josej.sanchez3@carm.es</email>
    </contact>
    <investigator>
      <last_name>Jose Javier Sánchez Blanco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fátima de la Cruz, MD</last_name>
      <email>fatimadelacruzv@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fátima de la Cruz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic Universitari de València</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª José Terol, MD</last_name>
      <email>terol39@mail.ono.es</email>
    </contact>
    <investigator>
      <last_name>Mª Jose Terol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Andreu, MD</last_name>
      <email>randreu69@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Andreu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Jesús Peñarrubia, MD</last_name>
      <email>mpenarrubiap@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mª Jesús Peñarrubia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

